| Thomas Bagley, CRNA | |
|
3914 Bella Ln, Foley, AL 36535-9086 | |
| (706) 717-0803 | |
| (251) 955-6969 |
| Full Name | Thomas Bagley |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 31 Years |
| Location | 3914 Bella Ln, Foley, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639402878 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | 1040907 (Alabama) | Secondary |
| 367500000X | Nurse Anesthetist, Certified Registered | RN062994 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Laredo Medical Center | Laredo, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hospitalist Medicine Physicians Of Texas - Dallas Pllc | 3678966819 | 19 |
News Archive
NovaBay Pharmaceuticals, Inc. today announced that its Aganocide® compounds demonstrate potent antifungal activity in an established pre-clinical infected nail model of onychomycosis. The study data will be presented tomorrow at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia.
Idera Pharmaceuticals today announced presentation of data from its randomized, double-blind, placebo-controlled Phase 2 trial that showed improvements from baseline of up to 90% in Psoriasis Area Severity Index scores in patients with moderate to severe plaque psoriasis following four weeks of treatment with the Toll-like Receptor antagonist IMO-3100.
A small study in the British Medical Journal suggests a new human genotype may be prone to variant Creutzfeldt-Jakob disease (vCJD).
The world's first clinical trial (SURGUVANT) evaluating anti-inflammatory use at the time of surgery in colon cancer patients to improve their cancer outcome has been published in scientific journal, BMC Cancer.
› Verified 8 days ago
| Entity Name | Northstar Anesthesia Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912978610 PECOS PAC ID: 7315907128 Enrollment ID: O20041015000685 |
News Archive
NovaBay Pharmaceuticals, Inc. today announced that its Aganocide® compounds demonstrate potent antifungal activity in an established pre-clinical infected nail model of onychomycosis. The study data will be presented tomorrow at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia.
Idera Pharmaceuticals today announced presentation of data from its randomized, double-blind, placebo-controlled Phase 2 trial that showed improvements from baseline of up to 90% in Psoriasis Area Severity Index scores in patients with moderate to severe plaque psoriasis following four weeks of treatment with the Toll-like Receptor antagonist IMO-3100.
A small study in the British Medical Journal suggests a new human genotype may be prone to variant Creutzfeldt-Jakob disease (vCJD).
The world's first clinical trial (SURGUVANT) evaluating anti-inflammatory use at the time of surgery in colon cancer patients to improve their cancer outcome has been published in scientific journal, BMC Cancer.
› Verified 8 days ago
| Entity Name | Seven Flags Anesthesia Associates, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841625878 PECOS PAC ID: 5395971865 Enrollment ID: O20131112001248 |
News Archive
NovaBay Pharmaceuticals, Inc. today announced that its Aganocide® compounds demonstrate potent antifungal activity in an established pre-clinical infected nail model of onychomycosis. The study data will be presented tomorrow at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia.
Idera Pharmaceuticals today announced presentation of data from its randomized, double-blind, placebo-controlled Phase 2 trial that showed improvements from baseline of up to 90% in Psoriasis Area Severity Index scores in patients with moderate to severe plaque psoriasis following four weeks of treatment with the Toll-like Receptor antagonist IMO-3100.
A small study in the British Medical Journal suggests a new human genotype may be prone to variant Creutzfeldt-Jakob disease (vCJD).
The world's first clinical trial (SURGUVANT) evaluating anti-inflammatory use at the time of surgery in colon cancer patients to improve their cancer outcome has been published in scientific journal, BMC Cancer.
› Verified 8 days ago
| Entity Name | Texas Ams Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174926125 PECOS PAC ID: 9133441769 Enrollment ID: O20141209001912 |
News Archive
NovaBay Pharmaceuticals, Inc. today announced that its Aganocide® compounds demonstrate potent antifungal activity in an established pre-clinical infected nail model of onychomycosis. The study data will be presented tomorrow at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia.
Idera Pharmaceuticals today announced presentation of data from its randomized, double-blind, placebo-controlled Phase 2 trial that showed improvements from baseline of up to 90% in Psoriasis Area Severity Index scores in patients with moderate to severe plaque psoriasis following four weeks of treatment with the Toll-like Receptor antagonist IMO-3100.
A small study in the British Medical Journal suggests a new human genotype may be prone to variant Creutzfeldt-Jakob disease (vCJD).
The world's first clinical trial (SURGUVANT) evaluating anti-inflammatory use at the time of surgery in colon cancer patients to improve their cancer outcome has been published in scientific journal, BMC Cancer.
› Verified 8 days ago
| Entity Name | Laredo Digestive Health Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275909780 PECOS PAC ID: 8921156464 Enrollment ID: O20160412000509 |
News Archive
NovaBay Pharmaceuticals, Inc. today announced that its Aganocide® compounds demonstrate potent antifungal activity in an established pre-clinical infected nail model of onychomycosis. The study data will be presented tomorrow at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia.
Idera Pharmaceuticals today announced presentation of data from its randomized, double-blind, placebo-controlled Phase 2 trial that showed improvements from baseline of up to 90% in Psoriasis Area Severity Index scores in patients with moderate to severe plaque psoriasis following four weeks of treatment with the Toll-like Receptor antagonist IMO-3100.
A small study in the British Medical Journal suggests a new human genotype may be prone to variant Creutzfeldt-Jakob disease (vCJD).
The world's first clinical trial (SURGUVANT) evaluating anti-inflammatory use at the time of surgery in colon cancer patients to improve their cancer outcome has been published in scientific journal, BMC Cancer.
› Verified 8 days ago
| Entity Name | Standard Anesthesia, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922546159 PECOS PAC ID: 1254616428 Enrollment ID: O20170330002103 |
News Archive
NovaBay Pharmaceuticals, Inc. today announced that its Aganocide® compounds demonstrate potent antifungal activity in an established pre-clinical infected nail model of onychomycosis. The study data will be presented tomorrow at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia.
Idera Pharmaceuticals today announced presentation of data from its randomized, double-blind, placebo-controlled Phase 2 trial that showed improvements from baseline of up to 90% in Psoriasis Area Severity Index scores in patients with moderate to severe plaque psoriasis following four weeks of treatment with the Toll-like Receptor antagonist IMO-3100.
A small study in the British Medical Journal suggests a new human genotype may be prone to variant Creutzfeldt-Jakob disease (vCJD).
The world's first clinical trial (SURGUVANT) evaluating anti-inflammatory use at the time of surgery in colon cancer patients to improve their cancer outcome has been published in scientific journal, BMC Cancer.
› Verified 8 days ago
| Entity Name | Hospitalist Medicine Physicians Of Texas - Dallas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164174124 PECOS PAC ID: 3678966819 Enrollment ID: O20220210000709 |
News Archive
NovaBay Pharmaceuticals, Inc. today announced that its Aganocide® compounds demonstrate potent antifungal activity in an established pre-clinical infected nail model of onychomycosis. The study data will be presented tomorrow at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia.
Idera Pharmaceuticals today announced presentation of data from its randomized, double-blind, placebo-controlled Phase 2 trial that showed improvements from baseline of up to 90% in Psoriasis Area Severity Index scores in patients with moderate to severe plaque psoriasis following four weeks of treatment with the Toll-like Receptor antagonist IMO-3100.
A small study in the British Medical Journal suggests a new human genotype may be prone to variant Creutzfeldt-Jakob disease (vCJD).
The world's first clinical trial (SURGUVANT) evaluating anti-inflammatory use at the time of surgery in colon cancer patients to improve their cancer outcome has been published in scientific journal, BMC Cancer.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Thomas Bagley, CRNA 3914 Bella Ln, Foley, AL 36535-9086 Ph: (706) 717-0803 | Thomas Bagley, CRNA 3914 Bella Ln, Foley, AL 36535-9086 Ph: (706) 717-0803 |
News Archive
NovaBay Pharmaceuticals, Inc. today announced that its Aganocide® compounds demonstrate potent antifungal activity in an established pre-clinical infected nail model of onychomycosis. The study data will be presented tomorrow at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia.
Idera Pharmaceuticals today announced presentation of data from its randomized, double-blind, placebo-controlled Phase 2 trial that showed improvements from baseline of up to 90% in Psoriasis Area Severity Index scores in patients with moderate to severe plaque psoriasis following four weeks of treatment with the Toll-like Receptor antagonist IMO-3100.
A small study in the British Medical Journal suggests a new human genotype may be prone to variant Creutzfeldt-Jakob disease (vCJD).
The world's first clinical trial (SURGUVANT) evaluating anti-inflammatory use at the time of surgery in colon cancer patients to improve their cancer outcome has been published in scientific journal, BMC Cancer.
› Verified 8 days ago
Mrs. Sharon Elaine Christopher, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1613 N Mckenzie St, Foley, AL 36535 Phone: 251-971-1028 Fax: 251-971-1029 | |
Sarah Castelin Willis, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 1613 N Mckenzie St, Foley, AL 36535 Phone: 251-949-3400 | |
Tammy Kay Jansen, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1613 S. Mckenzie Drive, Foley, AL 36535 Phone: 619-632-8183 |